RETACRIT is a biosimilar to epoetin alfa, a recombinant human erythropoietin, which is used to treat anemia associated with chronic kidney disease, chemotherapy-induced anemia in patients with certain types of cancer, and anemia due to zidovudine therapy in HIV-infected patients. It works by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood. RETACRIT is administered via injection under the skin or into a vein, and its dosage varies based on the patient's condition, body weight, and response to therapy. As with any medication, it is important to use RETACRIT under the guidance of a healthcare professional to ensure its safe and effective use.